Last reviewed · How we verify
Apatinib Combined With Docetaxel
Apatinib is a small molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor 2 (VEGFR2), inhibiting angiogenesis.
Apatinib is a small molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor 2 (VEGFR2), inhibiting angiogenesis. Used for Metastatic gastric cancer, Metastatic non-small cell lung cancer.
At a glance
| Generic name | Apatinib Combined With Docetaxel |
|---|---|
| Also known as | AITAN |
| Sponsor | Jiangsu ShengDiYa Medicine Co., Ltd. |
| Drug class | tyrosine kinase inhibitor |
| Target | VEGFR2 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Apatinib works by selectively inhibiting the tyrosine kinase activity of VEGFR2, which is involved in the regulation of angiogenesis. This leads to the inhibition of tumor growth and metastasis. Apatinib has been shown to have anti-tumor activity in various types of cancer.
Approved indications
- Metastatic gastric cancer
- Metastatic non-small cell lung cancer
Common side effects
- Diarrhea
- Fatigue
- Nausea
- Vomiting
- Anemia
- Thrombocytopenia
- Neutropenia
- Leukopenia
Key clinical trials
- AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 (PHASE3)
- Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing (PHASE2)
- Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC (PHASE2)
- HS-10502 Combination Treatment in Patients With Advanced Solid Tumors (PHASE1)
- A Prospective, Randomized, Open, Phase II Clinical Study of Chidamide in Combination with Camrelizumab and Apatinib for Advanced Esophageal Cancer (PHASE2)
- Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPC (PHASE2)
- Real-world Study of HER2-overexpressed Advanced Solid Tumors After Progression of First-line Standard Therapy
- SBRT/LDRT in Combination With Camrelizumab and Apatinib in Metastatic Non-small Cell Lung Cancer Patient Previously Treated With PD-1/L1 Inhibitor and Chemotherapy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: